Company Overview - Pagoda Biopharma-B (02565) experienced a maximum increase of over 15%, currently up 6.29% at HKD 56.65, with a trading volume of HKD 9.9416 million [1] - The company granted exclusive licensing rights to PDC FZ-LLC for the development, distribution, marketing, and commercialization of its core product Visepegenatide (PB-119) in the Middle East and Africa [1] - Visepegenatide (PB-119) is a weekly subcutaneous GLP-1 receptor agonist designed for the treatment of type 2 diabetes and weight management [1] Industry Insights - The adult diabetes prevalence rate in the Middle East and North Africa is as high as 16.2%, the highest globally [2] - The digestive and metabolic drug market, including diabetes treatment drugs, is the largest therapeutic area in the region, accounting for 20.4% market share, with a significant growth of 22.1% expected in Q1 2025 [2] - The global weight management drug market is projected to grow from USD 99.7 billion in 2020 to USD 112.8 billion by 2024, with a compound annual growth rate of 3.1%, and is expected to reach USD 277.4 billion by 2034 [2] - The demand for weight management drugs in the Middle East and Africa is anticipated to be the highest globally, potentially reaching a scale of USD 10 billion by 2034 [2]
港股异动 | 派格生物医药-B(02565)最高涨超15% GLP-1减重药出海中东及非洲